In the most recent trading session, Moderna (MRNA) closed at $31.25, indicating a -2.95% shift from the previous trading day.

Moderna (NasdaqGS:MRNA) recently experienced significant index changes, with the company being added to the Russell Midcap and Midcap Value indexes, while being dropped from several others. Over the ...

We may or may not be out of the woods, but focusing on the short-term performance of stocks is not the best strategy. Regardless of what happens over the next six months, it's still worth it to invest ...

A Turkish study finds Pfizer’s COVID-19 vaccine may cause temporary changes in corneal thickness and cell count, raising ...

Many of the 17 million projected to lose Medicaid coverage will turn to struggling free health clinics. They need more ...

Moderna's MRNA +4.30% Get Free Report short percent of float has risen 3.2% since its last report. The company recently reported that it has 65.59 million shares sold short, which is 23.56% of all ...

The S&P 500 fell 0.1% on Tuesday, July 8, 2025, after President Trump extended the deadline for "reciprocal" tariffs and ...

Moderna's messenger RNA flu vaccine candidate has shown has shown positive results in a late-stage trial. The biotechnology company said Monday its seasonal influenza vaccine candidate, mRNA-1010 ...

Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases.

The US Food and Drug Administration (FDA) has approved US mRNA specialist Moderna supplemental Biologics License Application ...

Pictet, a 220-year-old Swiss private bank, believes its ownership and management structure supports its ambition to be the ...

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.